Sabin IPV developed by Sinovac Biotech is a liquid trivalent vaccine (0.5 mL/dose) for intramuscular injection. It was generated from Sabin poliovirus type 1, 2, and 3 strains grown on Vero cells.
On April 8, 2019, the results of this study were published in The Journal for Infectious Diseases.
This analysis revealed that the studied sIPV demonstrated an immunogenicity profile non-inferior to that of the conventional IPV, as well as a good safety profile.
The launch of the studied sIPV may contribute to the polio eradication endgame in developing countries and the sustainment of a polio-free world.
Clinical Trial NCT03526978: An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants